Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Cryoport, Inc.CYRX · Entity 5125 | Director · President, CEO | August 11, 2026 | August 11, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Cryoport, Inc.
Report date August 11, 2026 · Filed August 11, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,201,814 |
Reported balance
After 2026-08-11 transaction · row 1
1 source rowRow 1 · 2026-08-11 · Sale · Disposed 28,800 · Balance 1,201,814 F1: The transactions reported in this Form 4 occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 11, 2026. The Rule 10b5-1 trading plan was terminated on August 11, 2026. F2: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.66 to $15.16, inclusive. The reporting person undertakes to provide to Cryoport, Inc., any security holder of Cryoport, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
Filing footnotes · ownership attribution and instrument terms
F1: The transactions reported in this Form 4 occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 11, 2026. The Rule 10b5-1 trading plan was terminated on August 11, 2026.
F2: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.66 to $15.16, inclusive. The reporting person undertakes to provide to Cryoport, Inc., any security holder of Cryoport, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 13, 2018 Filed Mar 16, 2018 01:42 UTC | Cryoport, Inc. CYRX · Entity 5125 | OtherCommon Stock | 80,558 | $3.57 | $287,592.06 |
DisclosureSEC source: 0001144204-18-015048 · tv488675_4.xml · nonDerivative · entry 1 SHELTON JERRELL · CIK 0001283212 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 267,819 F1 · balance_after: The last Form 4 reporting a transaction of common stock filed on August 30, 2016 erroneously did not take into account the 1-for-12 reverse stock split effective as of May 19, 2015. The number included here has been updated to reflect such reverse stock split. Read SEC document |
| May 23, 2017 Filed May 26, 2017 01:23 UTC | Cryoport, Inc. CYRX · Entity 5125 | GrantOption to Purchase Common Stock · Derivative | 340,000 | $3.44 Strike: $3.44 | $1,169,600.00 |
DisclosureSEC source: 0001144204-17-029664 · v467898_4.xml · derivative · entry 1 SHELTON JERRELL · CIK 0001283212 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 340,000 Underlying: Common Stock · 340,000 shares Expires 2027-05-23 F1 · derivative.exercise_date: 1/48 of the options vest on the 23rd of each month for 48 months beginning on 5/23/2017; provided that up to 1/2 of the options may accelerate base on achievement of certain performance goals. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.